RPRX — Royalty Pharma plc price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $68.68
- YTD price return
- +77.74%
- YTD total return
- +80.80%
- Market cap
- 39.4B
- Enterprise value
- 50.4B
- Shares outstanding
- 573.6M
- 52W low
- $37.31
- 52W high
- $70.37
- From 52W high
- -2.40%
- From 52W low
- +84.08%
- 52W range
- 95%$37.31–$70.37
- Beta
- 0.42
Volume
- Rel volume
- 0.78×
- 30D volume
- 3.4M
- 30D $ vol
- 217.2M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$6.3M
- Insider net 1Y
- −$62.5M
Form 4 transactions by trade date, as filed; latest on file 2026-10-05.
Fundamentals
- Sales (ttm)
- 2.6B
- Sales/share
- $4.56
- EPS (ttm)
- $1.17
- Book value/share
- $11.92
- Net margin
- 25.70%
- ROE
- 9.84%
- ROA
- 3.46%
- Debt / equity
- 1.11×
- Current ratio
- 1.29
Growth (CAGR, ttm) · 10Y
- Sales
- +11.37%+4.03%+2.74%n/a
- Net income
- -11.99%+53.90%-3.00%n/a
- Shares
- -0.63%-1.35%-1.13%n/a
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -6.81%+161.04%+6.16%n/a
- Sales/share
- +12.08%+5.45%+3.92%n/a
- Book value/share
- +7.27%+5.07%+4.55%n/a
- Dividend/share
- +6.33%+6.30%+6.70%n/a
- Price
- +75.45%+37.18%+10.09%n/a
- Total return
- +78.47%+40.54%+12.77%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 58.6×
- P/OI (ttm)
- 26.3×
- Fwd P/E
- 11.6×
- P/S (ttm)
- 15.1×
- P/B (mrq)
- 5.8×
- EV/EBITDA (fy)
- 33.6×
- EV/Sales (ttm)
- 19.3×
- Dividend yield (fwd)Div yield
- 1.37%
- Dividend yield (ttm)
- 1.37%
- Dividend/share (fwd)
- $0.94
- Buyback yield (realized, 1y)
- 0.63%
- Shareholder yield (realized, 1y)
- 2.00%
- Buyback yield (cash, ttm)
- 0.66%
- Shareholder yield (cash, ttm)
- 0.66%
Vs own 10Y history
- P/E
- 83rd
- P/OI
- 81st
- P/S
- 100th
- P/B
- 96th
Bar = where today’s multiple sits in RPRX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR −0.5%5Y CAGR −0.5%YoY −3.8%EPS (diluted)
5Y CAGR +6.2%5Y CAGR +6.2%YoY −51.5%Net income
5Y CAGR −4.6%5Y CAGR −4.6%YoY −49.1%Shares (diluted)
5Y +50.3%5Y +50.3%YoY −0.5%Dividend per share
YoY +6.8%About Royalty Pharma#
Data provided bySource: Twelve DataRoyalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.
New York, NY·100 employees·Biotechnology·royaltypharma.com·As of Oct 28, 2026
Recent filings#
- Nov 4Earnings · Earnings release — EPS $1.21 vs $1.18 est. (+2.5%); revenue $690.1M (+13% y/y) 1.7%
- Aug 5Earnings · Earnings release — EPS $1.32 vs $1.27 est. (+3.9%); revenue $674.1M (+16% y/y) 0.5%
ETFs holding RPRX#
18 of the 193 ETFs ChartRow carries live hold RPRX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VXF | Vanguard Extended Market ETF | 0.3% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.2% |
| IWR | iShares Russell Midcap ETF | 0.2% |
| VYM | Vanguard High Dividend Yield ETF | 0.1% |
| DGRO | iShares Core Dividend Growth ETF | 0.1% |
| VONV | Vanguard Russell 1000 Value ETF | 0.1% |
| IWD | iShares Russell 1000 Value ETF | 0.1% |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
